Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$14.84 - $24.79 $150,685 - $251,717
-10,154 Reduced 47.55%
11,201 $181,000
Q1 2023

May 15, 2023

BUY
$8.08 - $17.33 $172,548 - $370,082
21,355 New
21,355 $355,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Nine Point Two Capital LLC Portfolio

Follow Nine Point Two Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nine Point Two Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nine Point Two Capital LLC with notifications on news.